Clinical relevance of galectin-1 expression in non-small cell lung cancer patients by Carlini, María José et al.
Accepted Manuscript
Title: Clinical relevance of galectin-1 expression in non-small
cell lung cancer patients
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BACKGROUND: Identification of biomarkers in lung cancer, a leading cause of cancer-
related mortality, has a meaningful clinical relevance in the quest of novel prognostic 
factors and therapeutic targets. The glycan-binding protein galectin-1 (Gal-1) modulates 
tumor progression by mediating cell-cell and cell-extracellular matrix interactions, as well 
as angiogenesis and tumor immune-escape. Previous works reported the expression of Gal-
1 in lung cancer, although its clinical significance remains uncertain. OBJECTIVE: To 
assess the clinicopathologic relevance and prognostic value of Gal-1 expression in a cohort 
of 103 Stage I-III non-small cell lung cancer (NSCLC) patients. METHODS: Gal-1 
expression was determined by immunohistochemistry in tumor tissue samples. The 
percentage of immunoreactive tumor cells and stroma, as well as the presence of blood 
vessels with positively stained endothelium in the tumor and surrounding normal tissue, 
were recorded. Results were correlated with the clinicopathologic factors of the patients 
(Spearman's rank correlation coefficient, chi-square test) and overall survival by univariate 
(Kaplan Meier) and multivariate analyses (Cox regression hazard model). RESULTS: We 
did not observe significant associations between Gal-1 expression and relevant 
clinicopathologic features at diagnosis of NSCLC. However, Kaplan Meier analysis 
revealed a significant association between Gal-1 expression and overall survival, when Gal-
1 expression was analyzed on tumor cells alone (“tumor cell percentage”) or when an 
integrated score accounting for tumor cell as well as stromal expression of Gal-1 (“total 
score”) was assessed. Patients showing high Gal-1 expression evidenced a poorer clinical 
outcome. Furthermore, “total score” remained significantly associated with survival by 
multivariate Cox regression analysis in the whole cohort of patients, even when controlling 













for the classical predictors and prognostic factors of NSCLC. CONCLUSION: We 
conclude that Gal-1 expression may be a useful biomarker for better prediction of the 
clinical outcome and management of NSCLC patients.  














Lung cancer is the most frequent and one of the most deadly cancer types. In Argentina, the 
age-standardized mortality rates were 31.9 among men and 7.5 among women per 100000 
inhabitants per year (1990 to 2005), being the leading cause of cancer-related death in men 
and the fourth leading cause in women [1]. Most lung cancers (85%) are NSCLC, which 
consist of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Treatment 
options depend on stage of disease and include surgery, radiation, platinum doublet 
chemotherapy, and targeted therapies in some cases [2]. The most important prognostic 
factor for survival is the tumor, node, metastasis (TNM) system, which has been revised in 
2009 [3]. Nevertheless, data are still missing with regards to survival and predictive 
features, as even among patients at early stages of the disease, about 30% relapse and die 
within 5 years of surgery [4]. A better understanding of the mechanisms leading to adverse 
clinical outcomes is likely to improve therapeutic intervention of NSCLC patients.  
Anti-tumor immune responses play important roles in eradicating and suppressing the 
growth of several cancer types. However, tumors can evade immune surveillance through a 
number of immune escape mechanisms and immunosuppressive molecules [5], some of 
which have served as clinical biomarkers delineating the prognosis of cancer patients 
(reviewed in [6]). Gal-1 belongs to a family of soluble lectins defined by a common 
structural fold and a conserved carbohydrate recognition domain that recognizes glycans 
containing the disaccharide N-acetyllactosamine [7]. Secretion of Gal-1 has been shown to 
contribute to the immunosuppressive activity of melanoma, Hodgkin’s lymphoma and 
pancreatic carcinoma, suggesting the essential role of this protein in tumor-immune escape 
by tumors [8-10]. In lung cancer, several preclinical studies documented a link between 













Gal-1, immune escape and tumor progression [11, 12]. Furthermore, a prognostic 
significance of Gal-1 in human lung cancer has been proposed [13, 14].  
We undertook this study to provide a detailed retrospective assessment of Gal-1 expression 
in 103 cases of primary NSCLC stages I-III and analyzed its clinicopathologic role and 
prognostic significance. Our results indicate that an integrated score accounting for tumor 
as well as stromal expression of Gal-1 represents an independent prognostic factor of poor 
outcome in NSCLC patients.  














Materials and methods 
 
Patients and tumor specimens 
103 samples from patients with NSCLC were obtained from the "Hospital Italiano de 
Buenos Aires” for this retrospective analysis. Tissue specimens were obtained at surgery 
from untreated patients, fixed in 4% (v/v) formaldehyde in PBS immediately after removal 
and embedded in paraffin. The study included white individuals Curative resections were 
performed from 1997 through 2009. Staging was determined by the American Joint 
Committee on Cancer Guidelines, 7th edition [3]. Data on pathological findings and clinical 
follow-up were obtained from medical charts. All patients who died had clear evidence of 
uncontrolled tumor growth at the time of death. The Ethics Committees of the Institute of 
Oncology “Ángel H. Roffo” and the “Hospital Italiano de Buenos Aires” approved this 
study, which carefully followed the Declaration of Helsinki. The requirement of informed 
consent was waived as the study was based in the retrospective analyses of existing 
administrative and clinical data. Table 1 summarizes the clinical and pathological features 
of all cases.  
 
Immunohistochemistry 
Five μm-tissue sections were obtained from each tumor block on polylysine-coated slides. 
All sections were routinely deparaffinized and rehydrated before staining. Sections were 
treated with 0.3% hydrogen peroxide in water for 30 min to block endogenous peroxidase 
activity. Immunohistochemical staining of Gal-1 was performed using a streptavidin-biotin 
amplification method with the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, 













CA). Sections were incubated with normal horse serum in PBS for 45 min to block non-
specific binding before adding the affinity-purified rabbit anti-Gal-1 primary antibody 
(diluted 1:2000 in PBS) overnight at 4°C. After washing, secondary biotinylated universal 
antibody was added for 1 h at room temperature followed by Vectastain ABC reagent for 
30 min, washing between steps. The antigen-antibody complex was visualized with 
diaminobenzidine (Vector Laboratories, Burlingame, CA), counterstained with Mayer's 
hematoxylin, rehydrated, and then mounted with Canada synthetic balsam. Negative 
controls missing the primary antibody showed no immunoreactivity. The consistent 
expression of Gal-1 in peripheral nerves was used as an internal positive control. 
 
Quantification of Gal-1 expression 
Sections were coded and analyzed by two experienced observers without knowledge of 
patient evolution. The expression of Gal-1 was evaluated in the tumor cells and in the 
tumor stroma (cells and extracellular matrix) and categorized according to the percentage 
of positive stained cells (score from 0 to 3, where 0 = negative, 1 ≤ 10%, 2 = 11–50%, and 
3 ≥ 51%) and the intensity of staining (0= negative, 1= weak, 2= moderate and 3= strong). 
By means of these percentages, patients were divided into two groups showing low or high 
Gal-1 expression by using 0% and 50% as cut-off values for tumor cells and tumor stroma, 
respectively. On this basis, “tumor cell percentage” and “tumor stroma percentage” were 
recorded. A combined score was also calculated for each tumor with a double-entry table 
combining the percentage and intensity values, establishing the variables “tumor cell score” 
and “tumor stroma score” (Table 2). Score data were dichotomized into two groups of low 
and high Gal-1 score using a cut-off value of 2. Also, an overall score (total score) 
integrating the dichotomized percentages of both tumor cells and stromal cells was 













calculated and dichotomized establishing the high Total Score group when percentage was 
high for both tumor cells and stroma. Endothelial cells delineating blood vessels were also 
analyzed for Gal-1 immunoreactivity. Cases were segregated into a low or high expression 
group using a cut-off of 10% of immunoreactive endothelial cells in both tumor and 
surrounding normal tissue (tumor vessels, normal vessels).  
 
Statistical analyses 
For statistical purposes, all variables were dichotomized into a low-expression group and a 
high-expression group. Statistical correlations between the variables under study were 
assessed with Spearman's rank correlation coefficient. Dependence among the variables and 
the clinicopathologic parameters was evaluated by χ2 test. Global survival was measured 
from the date of surgery to the time of the last follow-up visit or death. Survival curves 
were plotted according to the Kaplan-Meier method and the P value of the likelihood-ratio 
test was used to assess statistical significance of the hazard ratios. To identify independent 
prognostic factors, we used the Cox proportional hazard model. P values are based on 2-
sided tests, and significance was set at P ≤ .05. 















Gal-1 Expression in Human NSCLC  
Gal-1 was assessed by immunohistochemistry in 103 tissue specimens derived from 
primary NSCLC. Tumor cells showed positive diffuse or granular staining for Gal-1 that 
was exclusively cytoplasmic (Fig. 1a). Gal-1 expression was detected in 53/103 (51.5%) 
NSCLC samples (“tumor cell percentage”). The tumor stroma displayed widespread Gal-1 
staining both in stromal cells and the extracellular milieu (Fig. 1c), with 85/103 (82.5%) 
immunoreactive cases in more than 50% of total tumor stroma (“tumor stroma 
percentage”). Finally, a score integrating positivity of both tumor cells and stroma was 
calculated (“total score”). In addition, we assessed Gal-1 staining in endothelial cells to 
analyze a possible correlation with angiogenesis, both at the tumor (Fig. 1e,f) and normal 
tissue (Fig. 1g,h) (tumor vessels and normal vessels). Notably, 58/102 (56.9%) and 44/90 
(48.9%) cases showed Gal-1 expression in vessels associated to tumoral and normal tissue, 
respectively. Remarkably, a strong correlation was observed between Gal-1 expression in 
vessels of tumoral and normal tissue (Spearman's rank correlation, R: 0.741, P <0.0001).  
 
Gal-1 Expression and Clinicopathologic Features in Human NSCLC 
Possible associations between the variables under study and clinicopathologic parameters 
(T, N, stage, age, sex and histologic type) were analyzed by chi square test. No significant 
associations were observed, except for a higher proportion of cases with high Gal-1 
expression in tumor stroma (“tumor stroma score”) in adenocarcinomas versus squamous 
cell carcinomas (93.4% versus 75%, P =0.018).  













To gain further insights into the clinical relevance of Gal-1 expression in NSCLC, we 
analyzed the possible correlation between Gal-1 expression and clinicopathologic features 
(Table 3). No significant correlation was observed with regards to T, N, stage or age, 
except for a weak correlation between tumor cell score and age (Table 3).  
 
Gal-1 Expression and Survival of Human NSCLC 
In our cohort of NSCLC patients the 5-year overall survival rate was 86% for Stage Ia, 80% 
for stage Ib, 73% for Stage IIa, 33% for Stage IIb and 9% for Stage III, and this 
classification predicted survival reliably (P =5.88E-11). We examined whether dichotomized 
variables of Gal-1 expression could also predict disease-specific. No significant association 
was found between different variables of Gal-1 expression and disease-free survival (data 
not shown). On the other hand, univariate analysis for overall survival indicated that “tumor 
stroma percentage”, “tumor stroma score”, “tumor vessels” and “normal vessels” were 
found to be not associated with overall survival. However, when the variables “tumor cell 
percentage” and “total score” were analyzed, we could discriminate patients into low and 
high risk groups with statistical significance (P = 0.029 and P =0.033, respectively). Figures 
2a and 2b illustrate the Kaplan-Meier plots of overall survival curves showing the low and 
high Gal-1 expression groups. High Gal-1 expression was associated with decreased 5-year 
survival when analyzed according to “tumor cell percentage” and “total score” parameters. 
On the other hand, the overall survival curves for the combined percentage and intensity 
values of Gal-1 immunostaining in tumor cells (“tumor cell score”) were similar to those 
shown by the “tumor cell percentage”, indicating that these two variables do not have 
significant independent outcomes (data not shown). Importantly, by multivariate Cox 













regression analysis, the “total score” remained significantly associated with survival (P = 
0.047; Table 4) in the whole cohort of patients, even when controlling for the classical 
predictors and prognostic factors such as T, N, histologic type (which reliably predicted 
survival) and sex, whereas the “tumor cell percentage” exhibited a borderline significance 
in this analysis (P = 0.084, data not shown).  
Finally, we performed an additional multivariate analysis by creating a decision tree 
to assess the effect of specific variables on survival, including known predictors of NSCLC 
prognosis (stage, histologic type, age, sex) and the variables of Gal-1 expression which 
were found to be significant by univariate analysis (“tumor cell percentage” or “total 
score”). In two separated tree-structured models, “tumor cell percentage” and “total score” 
differentiated survival to the best and were allocated to node I. Patients with the worse 
clinical outcome (high “tumor cell percentage” or “total score”) were further dichotomized 
by stage in the second node (data not shown).  















In this retrospective study, we evaluated Gal-1 expression in tumor cells and stroma of 
human NSCLC samples to assess whether this information could offer any prognostic value 
for the management of this cancer type. We report an association between increased Gal-1 
expression and decreased overall survival in a cohort of 103 NSCLC patients, after 
adjustment for other predictors of outcome. This finding may be relevant to guide improved 
medical treatment and, together with several lines of preclinical studies, our study 
establishes the rationale for targeting Gal-1 expression and/or disrupting its binding to 
specific glycans in human NSCLC therapy. 
Expression of Gal-1 has been shown to be associated with disease progression and/or 
overall survival by univariate analysis in gastric cancer [15], cervical cancer [16] and 
pancreatic ductal adenocarcinoma [17]. However, only few studies have demonstrated that 
Gal-1 could be an independent prognostic factor by conducting multivariate analysis [18, 
19]. Regarding lung cancer, in tissue microarrays from patients with lung adenocarcinoma, 
Gal-1 expression scores were higher for stage III compared with stage I or II patients [20]. 
Here we could observe no significant associations between tumor or stromal Gal-1 
expression and the most relevant clinicopathologic features of NSCLC at diagnosis. 
However, we did observe a positive correlation between high Gal-1 expression and 
decreased 5-year survival when the “tumor cell percentage” and the “total score” for Gal-1 
expression were analyzed. In a previous study, Szöke et al showed poorer prognosis in 
NSCLC and SCLC lung tumors showing Gal-1 expression [13]. The authors also evaluated 
Gal-3 expression and binding activities in lung cancer patients and demonstrated that Gal-3 
negative cases displayed improved survival rate [13, 14].  













Gal-1 is secreted to the extracellular milieu through a still poorly understood 
unconventional pathway and interacts with cell surface glycosylated ligands to modulate 
immune escape, angiogenesis and tumor cell migration [21]. However, Gal-1 can be also 
found in the cytoplasmic and nuclear compartments and plays intracellular roles by 
modulating signaling pathways leading to tumorigenesis via protein-protein interactions 
with the cytoplasmic H-RAS oncogene [22]. We found that about 50% of NSCLC samples 
exhibited specific intracellular Gal-1 staining within the cytoplasmic compartment of tumor 
cells. Remarkably, Gal-1 plays multiple roles in lung cancer that lead to tumor progression 
and metastasis. In human NSCLC cell lines, endogenous Gal-1 expression contributes to 
cell migration, invasion, anchorage-independent growth and resistance to cisplatin in vitro 
and to tumor growth in vivo, through mechanisms dependent on activation of p38, ERK1/2 
and NF-κB signaling pathways and cyclooxygenase-2 up-regulation [20]. Interestingly, 
while intracellular Gal-1 signaling appeared to be important for promoting lung cancer 
progression, NSCLC tumor cells secrete low levels of Gal-1 and were non-responsive to 
treatment with exogenous Gal-1 [17]. Also, in oral squamous cell carcinoma and lung 
adenocarcinoma cell lines Gal-1 expression correlated with invasiveness [23]. Furthermore, 
Gal-1 has been shown to promote lung cancer metastasis by amplifying integrin α6β4 and 
Notch1/Jagged2 signaling pathways [24].  
In addition to the activities displayed by Gal-1 on cancer cells themselves, Gal-1 
also contributes to tumor progression by shaping the tumor microenvironment through its 
ability to promote tumor-immune escape [25] and modulate angiogenic sprouting [26]. 
Silencing Gal-1 expression in the 4T1 breast tumor model induced a marked reduction of 
both tumor growth and the number of lung metastases [27]. This effect was abrogated when 













mice were inoculated with wild-type 4T1 tumor cells in their contralateral flank, suggesting 
involvement of a systemic modulation of the immune response [18]. Moreover, Gal-1 
attenuation in 4T1 cells also reduced the frequency of CD4+ CD25+ Foxp3+ regulatory T 
cells within the tumor, draining lymph nodes, spleen and lung metastases [18]. In human 
and mouse lung tumors, tumor-derived Gal-1 has been reported to be a critical mediator 
that instructs dendritic cells to express and release heparin-binding epidermal growth factor, 
which, in turn, promotes tumor progression [11]. In addition, in the Lewis lung carcinoma 
(LLC) model, tumor derived-Gal-1 induces tumor growth and metastasis through 
impairment of T cell mediated immune responses [12]. Moreover, in Kaposi’s sarcoma, a 
highly vascular tumor, we found that targeted disruption of Gal-1-N-glycan interactions 
eliminated hypoxia-driven angiogenesis and suppressed tumorigenesis [26]. In addition, in 
prostate cancer targeting Gal-1 abrogated neovascularization-related processes [28]. 
Furthermore, targeting Gal-1 in melanoma cells controlled both vascular and 
immunosuppressive programs [9, 29, 30]. Altogether, these preclinical observations 
highlight the relevance of Gal-1 as an emerging therapeutic target in a number of cancers. 
However, the lack of more definitive clinical data precluded the translation of these 
findings to clinical settings. Our results in NSCLC patients support the notion that Gal-1 
expression in lung cancer is associated with disease progression and unfavorable prognosis.  
Gal-1 expression has been reported to be either restricted to the tumor stroma [15, 
16] or found in both tumor cells and stroma [15, 18, 20, 31]. Here we showed that in 
NSCLC Gal-1 is widely expressed in the tumor stroma. Indeed, with the exception of two 
cases, all samples of NSCLC that were negative for Gal-1 in tumor cells (about 50%) 
presented positive stromal staining. This group of patients that showed only stromal 













staining evidenced a better survival compared with the remaining set of patients that 
expressed Gal-1 in both tumor cells and the stroma (data not shown). This observation 
suggests that the expression of tumoral Gal-1 is a key prognostic factor which determines 
the evolution of the disease. The importance of host versus tumoral Gal-1 was previously 
analyzed in LLC tumor progression. Using different experimental strategies, the authors 
found that tumoral Gal-1 was more important than stromal Gal-1 to promote tumor growth, 
immunosuppression and metastasis [19]. Based on these findings, we hypothesize that Gal-
1 expression in tumor cells may contribute to NSCLC progression and, although in our 
study the impact on survival was only of borderline significance when multivariate analysis 
was performed, we assume that the assessment of a larger cohort of patients will reveal a 
much more significant association. Furthermore, when higher expression in stroma and 
tumor cells was combined (high “total score”), the impact in survival reached statistical 
significance when multivariate analysis was used. Also, in a different multivariate analysis, 
in two separated tree-structured models, the “tumor cell percentage” and the “total score” 
discriminated survival to the best and were allocated to node I. 
Besides global assessment of Gal-1 expression in the tumor stroma, we evaluated 
whether Gal-1 was particularly expressed in endothelial cells associated to tumor or normal 
tissue. We observed that about 50% of NSCLC samples showed Gal-1 expression in blood 
vessels within both tumor and normal tissue, showing an important correlation of Gal-1 
expression in the two compartments. It is possible to speculate that factors secreted by these 
tumors may contribute to induce Gal-1 expression by endothelial cells in both tumor and 
normal tissue. This observation could be associated to the field of cancerization described 
in lung airways, where molecular abnormalities appear early in lung cancer pathogenesis 













and are shared between the tumor and adjacent histologically normal tissue [32]. However, 
in spite of these possible outcomes, these parameters did not reach a significant impact on 
patients’ survival. 
In summary, in this study we have demonstrated using single or combined parameters of 
tumor evolution, the clinical relevance of Gal-1 expression in human NSCLC. Our results 
show that Gal-1 expression may be a useful biomarker for a better prediction of tumor 
evolution for optimizing adjuvant treatments. The development of novel molecular 
approaches targeting Gal-1 or its specific glycans will be of particular importance either 
alone or in combination with current therapeutic modalities in order to tailor more selective 
treatments for lung cancer patients. 
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Table 1 Clinicopathologic parameters in patients with NSCLC. The study included white 
individuals (median age, 64 years; range, 45-85; median survival at five years, 52.5 months; 
range, 1-60). 
 Number of cases (%) a 
Sex (n=103)   
Male  69 (66.9%) 
Female  34 (33.0%) 
Histologic type (n=96)                   
Squamous Cell Carcinoma  24 (25.0%) 
Adenocarcinoma  61 (63.5%) 
Other 11 (11.5%) 
Stage (n=101)  
Ia  29 (28.7%) 
Ib  31 (30.7%) 
IIa  24 (23.8%) 
IIb  6 (5.9%) 
IIIa  11 (10.9%) 
Tumor size (n=103)  
1a  16 (15.5%) 
1b  22 (21.4%) 
2a  41 (39.8%) 
2b  14 (13.6%) 
3a  10 (9.7%) 
Lymph node status (n=100)  
0  76 (76%) 
1  16 (16%) 
2  8 (8%) 
awhere columns do not sum to the total, data were 
missing or unknown 
 
 













Table 2 Double entry table combining the percentage and intensity values of Gal-1 




 Intensity value 
 0 1 2 3 
0 0    
1  1 1 2 










3  3 3 4 













Table 3 Correlation between variables associated with Gal-1 expression and the main 
relevant parameters in lung cancer 
 
  
Tumor size Lymph node status Age 
Correlation 
coefficient 0.039 -0.033 0.138 
Tumor cell 
percentage 
p-value 0.695 0.745 0.166 
     
Correlation 
coefficient -0.029 0.140 0.003 Tumor stroma percentage p-value 0.770 0.164 0.974 
     
Correlation 
coefficient -0.007 -0.076 0.217 Tumor cell score p-value 0.948 0.452 0.028* 
     
Correlation 
coefficient 0.022 0.028 -0.033 Tumor stroma score p-value 0.824 0.784 0.742 
     
Correlation 
coefficient -0.014 0.067 -0.067 Tumor vessels 
p-value 0.886 0.508 0.504 
     
Correlation 
coefficient 0.035 0.031 -0.047 Normal vessels p-value 0.743 0.775 0.660 
     
Correlation 
coefficient 0.110 -0.032 0.035 Total score  

















Table 4 Cox proportional hazards model for the “total score” of Gal-1 expression in stage 
I-III NSCLC. Reference value: “total score” 
 
 COEF β (95% CI) P VALUE 
RISK RATIO FOR 
MORTALITY 
Lymph node status 
(none/intrapulmonary) 
1.381 (1.801 – 8.782) 0.001 3.977 
Histologic type  
(ADC, SCC or other) 
0.758 (1.078 – 4.223) 0.030 2.133 
 
Tumor size  
(1a, 1b, 2a, 2b or 3a) 
0.763 (1.407 - 3.268) 0.000 2.144 
 
Total score  
(low/high) 
0.894 (1.011 - 5.914) 0.047 2.446 
ADC: adenocarcinoma; SCC: squamous cell carcinoma 
 













Legends to figures 
 
Fig. 1 Representative microphotographs of Gal-1 expression in tumor cells (A,B); tumor 
stroma (C,D); and endothelial cells in the tumor (E,F) and normal (G,H) tissue in human 
non-small cell lung cancer (NSCLC). Inset shows Gal-1 expression in peripheral nerves 
used as an internal positive control (H). Arrows indicate endothelial cells delineating blood 
vessels. Scale bar: 50 μM 
 
Fig. 2 Overall survival plots according to Kaplan-Meier’s method for the groups defined on 
the basis of Gal-1 expression in tumor cells (“tumor cell percentage”) (A; P value= 0.029) 
or expression in both tumor cells and stroma (“total score”) (B; P value= 0.033) 
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Figure 2
